Prof. dr. A.F.H. Stalenhoef, vice chairman
Biography
Name: Anton F.H. Stalenhoef
Place of Birth: Amersfoort, the Netherlands
Date of Birth: 17 October 1947
Nationality: Dutch
Education
M.D. degree: 1974, Medical Faculty, Catholic University Nijmegen
Clin. Training: University Hospital Nijmegen 1979 Internist
PhD Thesis: 1982, Nijmegen: "Metabolic studies in various forms of hypertriglyceridemia in man"
Awards
Clinical Investigator of the Netherlands Heart Foundation (1988-1992).
Functions
1979- : Staff Member, Department of General Internal Medicine, University Medical Center Nijmegen 1982-1983: Visiting Scientist, CVRI, School of Medicine, University of California, San Francisco, U.S.A. (Director: dr. R.J. Havel)
1984: Associate Professor of Medicine, Department of Medicine, Medical Faculty, University of Nijmegen
1997 - : Professor of Medicine (Atherogenesis), Department of Medicine, University Medical Center Nijmegen, University of Nijmegen
Memberships
Dutch Internist Society
Dutch Society for the Investigation of Diabetes
Dutch Lipoprotein Club (Chairman -2002)
Dutch Association of Atherosclerosis and Vascular Biology (Vice Chairman)
Dutch Atherosclerosis Society (Vice Chairman)
Dutch Association of Vascular Medicine (Chairman)
European Society of Clinical Investigation
European Atherosclerosis Society European Lipoprotein Club (Committee member 1992-97)
American Heart Association, Arteriosclerosis Council
Atorvastatin Research Award Committee (Member)
Fields of Research Interest
Atherosclerosis
Lipoprotein metabolism
Hyperlipidemia
Cardiovascular disease
Diabetes mellitus
Cytokines
Inflammation
Publications
Over 150 peer-reviewed papers in international journals
Selection of publications A.F.H. Stalenhoef:
Bredie, S.J.H., Kiemeney, L.A.L.M., Haan, A.F.J. de, Demacker, P.N.M. & Stalenhoef, A.F.H. (1996). Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet, 58(4), 812-822.
Kroon, A.A., Aengevaeren, W.R.M., Werf, T. van der, Uijen, G.J.H., Reiber, J.H.C., Bruschke, A.V.G. & Stalenhoef, A.F.H. (1996). The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation, 93, 1826-1835.
Kroon, A.A., Asten, W.N.J.C. van & Stalenhoef, A.F.H. (1996). The effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med, 125, 945-954.
Netea, M.G., Demacker, P.N.M., Kullberg, B.J., Boerman, O.C., Verschueren, C.M.M., Stalenhoef, A.F.H. & Meer, J.W.M. van der (1996). Low density lipoprotein receptor deficient mice are protected against endotoxemia and severe gram-negative infections. J Clin Invest, 97, 1366-1372.
Rijke, Y.B. de, Demacker, P.N.M., Assen, N.A., Schoots, L.M., Katan, M.B. & Stalenhoef, A.F.H. (1996). Red wine consumption does not affect oxidizability of low-density lipoproteins in volunteers. Am J Clin Nutr, 63, 329-334.
Juo, S.H., Bredie, S.J.H., Kiemeney, L.A.L.M., Demacker, P.N.M. & Stalenhoef, A.F.H. (1998). A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Am J Hum Genet, 63, 586-595.
Bont, N. de, Netea, M.G., Demacker, P.N.M., Verschueren, I., Kullberg, B.J., Dijk, K.W., Meer, J.W.M. van der & Stalenhoef, A.F.H. (1999). Apoliprotein E knock-out mice are highly susceptible to endotoxemia an Klebsiella pneumoniae infection. J Lipid Res, 40, 680-685.
Hoffer, M.J.V., Snieder, H., Bredie, S.J.H., Demacker, P.N.M., Kastelein, J.J.P., Frants, R.R. & Stalenhoef, A.F.H. (2000). The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined in hyperlipidemia. Atherosclerosis, 151, 443-450.
Stalenhoef, A.F.H., Graaf, J. de, Wittekoek, M.E., Bredie, S.J.H., Demacker, P.N.M. & Kastelein, J.J.P. (2000). The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogenety and oxidizability in patients with hypertrygliceridemia. Atherosclerosis, 153, 129-138.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hyper-cholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-81.